Skip to main content
AVECHO BIOTECHNOLOGY LIMITED logo

AVECHO BIOTECHNOLOGY LIMITED — Investor Relations & Filings

Ticker · AVE ISIN · AU0000047441 LEI · 529900FA9G9T82C2LV25 ASX Manufacturing
Open in API
Filings indexed 881 across all filing types
Latest filing 2023-05-22 AGM Information
Country AU Australia
Listing ASX AVE

About AVECHO BIOTECHNOLOGY LIMITED

https://avecho.com.au/

Avecho Biotechnology Limited develops and commercializes human and animal health products using its proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM®). Derived from Vitamin E, TPM® is designed to enhance the solubility and absorption of active ingredients through the skin and digestive tract. The company focuses on applying this technology to pharmaceuticals, nutraceuticals, and animal health sectors. A primary area of development includes medicinal cannabis, where Avecho has produced high-bioavailability cannabidiol (CBD) softgel capsules for therapeutic use. The company’s portfolio also includes applications in pain management and dermatology, leveraging TPM® to improve the delivery of poorly soluble molecules and enhance the efficacy of existing treatments.

Recent filings

Filing Released Lang Actions
Chair's Address and CEO Presentation 21 pages 1.8MB
AGM Information Classification · 95% confidence The document is an ASX announcement dated 23 May 2023, containing the Chair's Address and CEO Presentation for the Annual General Meeting (AGM) of Avecho Biotechnology Limited. It includes detailed presentations and speeches given at the AGM, discussing company updates, clinical trials, business development, and capital raising. The content is focused on materials shared during the AGM rather than a formal annual report or financial statements. The length is substantial (15,000 characters), indicating it is not a brief announcement but actual AGM materials. Therefore, the document fits the category of AGM Information (AGM-R).
2023-05-22 English
2023 Annual General Meeting Results 2 pages 80.8KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an ASX announcement dated 23 May 2023, titled '2023 Annual General Meeting Results'. It provides detailed voting results for resolutions passed at the Annual General Meeting (AGM) of Avecho Biotechnology Limited. The content includes proxy votes, resolution details, and outcomes, consistent with official voting results disclosures. There is no indication that this is the AGM presentation material itself, nor is it a full annual report or financial statement. The document is focused on the official announcement of voting results from the AGM, which aligns with the category 'Declaration of Voting Results & Voting Rights Announcements (DVA)'. The document length is about 5171 characters, which is sufficient to contain detailed voting results rather than a mere announcement of a report publication. Therefore, the correct classification is DVA with high confidence.
2023-05-22 English
Avecho licenses TPM for use in cancer drugs 3 pages 98.7KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 22 May 2023 about Avecho entering a strategic partnership with Arthur Group for licensing and development of cancer drugs. It details the terms of the agreement, market potential, and forward-looking statements. There are no financial statements, quarterly or annual results, nor is this a report or transcript. The content is a corporate announcement about a business development and partnership, not a financial report or regulatory filing. The document length is 9585 characters, which is substantial but the content is clearly an announcement of a strategic partnership and licensing agreement. Therefore, the most appropriate classification is Capital/Financing Update (CAP), as it relates to company fundraising, financing activities, or capital structure changes, here specifically a licensing and development agreement with revenue sharing terms.
2023-05-21 English
Withdrawal of AGM Resolutions 5(c) and 5(d) 1 page
AGM Information Classification · 90% confidence The document is an ASX announcement dated 18 May 2023 regarding the withdrawal of certain AGM resolutions (5(c) and 5(d)) related to the 2023 Notice of Annual General Meeting. It discusses changes to the business of the upcoming AGM and shareholder approval matters. The content is focused on AGM resolutions and meeting details rather than the full AGM materials or presentations. The document length is short (2327 characters), and it is an announcement about AGM resolutions, not the AGM report or presentation itself. Therefore, the most appropriate classification is AGM Information (AGM-R), which covers presentations and materials shared during the AGM or related announcements about AGM business.
2023-05-17 English
AVE commences manufacturing for Phase III trial 3 pages 304.1KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 17 May 2023 from Avecho Biotechnology Limited. It discusses the commencement of manufacturing activities for a pivotal Phase III clinical trial product, details about the contract manufacturer Procaps Group, and the company's capital raise to fund the trial. The content focuses on operational updates related to manufacturing and financing for a clinical trial, without any financial statements, regulatory certifications, or detailed financial performance data. It is not a full annual or interim report, audit report, earnings release, or any other detailed financial or governance report. The document is a corporate announcement about manufacturing and capital raising activities, which fits best under Capital/Financing Update (CAP). The document length (8338 characters) and content confirm it is a substantive announcement rather than a brief notice or report publication announcement.
2023-05-16 English
Change in Substantial Holding 2 pages 434.2KB
Regulatory Filings
2023-05-15 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.